BioVentrix, Inc. (BVXX)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income | -7.67M |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BVXX
BioVentrix is a medical device company focused on developing, manufacturing and commercializing proprietary devices to restore left ventricular function in heart failure patients with reduced ejection fraction. Our lead device program, the Revivent System, has a CE mark in Europe and is in its pivotal trial in the United States.
News
BioVentrix, Heart Failure Medical Device Developer, Files for Nasdaq IPO
BioVentrix, a developer of therapies for heart failure, filed an S-1 to list on the Nasdaq Capital Market under the ticker BVXX. The company is pursuing an IPO to fund its pivotal U.S. trial for its R...
BioVentrix IPO Registration Document (S-1)
BioVentrix has filed to go public with an IPO on the NASDAQ
Cardiac medical device developer BioVentrix files for an $17 million IPO
BioVentrix, a medical device firm developing minimally invasive treatments for heart failure, filed on Thursday with the SEC to raise up to $17 million in an initial public offering.